

# DEOXYNUCLEOSIDE ANALOGS IN CANCER THERAPY

# CANCER DRUG DISCOVERY AND DEVELOPMENT

---

Beverly A. Teicher, Series Editor

- Regional Cancer Therapy**, edited by *Peter M. Schlag and Ulrike Stein*, 2007
- Gene Therapy for Cancer**, edited by *Kelly K. Hunt, Stephan A. Vorburger, and Stephen G. Swisher*, 2007
- Deoxynucleoside Analogs in Cancer Therapy**, edited by *Godefridus J. Peters*, 2006
- Cancer Drug Resistance**, edited by *Beverly A. Teicher*, 2006
- Histone Deacetylases: Transcriptional Regulation and Other Cellular Functions**, edited by *Eric Verdin*, 2006
- Immunotherapy of Cancer**, edited by *Mary L. Disis*, 2006
- Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect**, edited by *Giampietro Gasparini and Daniel F. Hayes*, 2006
- Protein Tyrosine Kinases: From Inhibitors to Useful Drugs**, edited by *Doriana Fabbro and Frank McCormick*, 2005
- Bone Metastasis: Experimental and Clinical Therapeutics**, edited by *Gurmit Singh and Shafaat A. Rabbani*, 2005
- The Oncogenomics Handbook**, edited by *William J. LaRochelle and Richard A. Shimkets*, 2005
- Camptothecins in Cancer Therapy**, edited by *Thomas G. Burke and Val R. Adams*, 2005
- Combination Cancer Therapy: Modulators and Potentiators**, edited by *Gary K. Schwartz*, 2005
- Death Receptors in Cancer Therapy**, edited by *Wafik S. El-Deiry*, 2005
- Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention**, edited by *Gary J. Kelloff, Ernest T. Hawk, and Caroline C. Sigman*, 2005
- Proteasome Inhibitors in Cancer Therapy**, edited by *Julian Adams*, 2004
- Nucleic Acid Therapeutics in Cancer**, edited by *Alan M. Gewirtz*, 2004
- Cancer Chemoprevention, Volume 1: Promising Cancer Chemopreventive Agents**, edited by *Gary J. Kelloff, Ernest T. Hawk, and Caroline C. Sigman*, 2004
- DNA Repair in Cancer Therapy**, edited by *Lawrence C. Panasci and Moulay A. Alaoui-Jamali*, 2004
- Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics**, edited by *George Morstyn, MaryAnn Foote, and Graham J. Lieschke*, 2004
- Handbook of Anticancer Pharmacokinetics and Pharmacodynamics**, edited by *William D. Figg and Howard L. McLeod*, 2004
- Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition**, edited by *Beverly A. Teicher and Paul A. Andrews*, 2004
- Handbook of Cancer Vaccines**, edited by *Michael A. Morse, Timothy M. Clay, and Kim H. Lyerly*, 2004
- Drug Delivery Systems in Cancer Therapy**, edited by *Dennis M. Brown*, 2003
- Oncogene-Directed Therapies**, edited by *Janusz Rak*, 2003
- Cell Cycle Inhibitors in Cancer Therapy: Current Strategies**, edited by *Antonio Giordano and Kenneth J. Soprano*, 2003
- Fluoropyrimidines in Cancer Therapy**, edited by *Youcef M. Rustum*, 2003
- Chemoradiation in Cancer Therapy**, edited by *Hak Choy*, 2003
- Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins**, edited by *Nicholas B. La Thangue and Lan R. Bandaru*, 2002
- Tumor Targeting in Cancer Therapy**, edited by *Michel Pagé*, 2002
- Hormone Therapy in Breast and Prostate Cancer**, edited by *V. Craig Jordan and Barrington J. A. Furr*, 2002
- Tumor Models in Cancer Research**, edited by *Beverly A. Teicher*, 2002
- Tumor Suppressor Genes in Human Cancer**, edited by *David E. Fisher*, 2001
- Matrix Metalloproteinase Inhibitors in Cancer Therapy**, edited by *Neil J. Clendeninn and Krzysztof Appelt*, 2001
- Farnesyltransferase Inhibitors in Cancer**, edited by *Saïd M. Sebti and Andrew D. Hamilton*, 2001
- Platinum-Based Drugs in Cancer Therapy**, edited by *Lloyd R. Kelland and Nicholas P. Farrell*, 2000

DEOXYNUCLEOSIDE  
ANALOGS  
IN CANCER THERAPY

*Edited by*

GODEFRIDUS J. PETERS, PhD

*Professor of Medical Oncology, VU University Medical Center  
Amsterdam, The Netherlands*



HUMANA PRESS  
TOTOWA, NEW JERSEY

© 2006 Humana Press Inc.  
999 Riverview Drive, Suite 208  
Totowa, New Jersey 07512

[www.humanapress.com](http://www.humanapress.com)

All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher.

All articles, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher.

Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the information published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication. Notwithstanding, as new research, changes in government regulations, and knowledge from clinical experience relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug. It is the responsibility of the treating physician to determine dosages and treatment strategies for individual patients. Further it is the responsibility of the health care provider to ascertain the Food and Drug Administration status of each drug or device used in their clinical practice. The publisher, editors, and authors are not responsible for errors or omissions or for any consequences from the application of the information presented in this book and make no warranty, express or implied, with respect to the contents in this publication.

Cover design by Patricia F. Cleary

This publication is printed on acid-free paper. 

ANSI Z39.48-1984 (American National Standards Institute)

Permanence of Paper for Printed Library Materials

For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; E-mail: [orders@humanapr.com](mailto:orders@humanapr.com); or visit our Website: [www.humanapress.com](http://www.humanapress.com)

#### **Photocopy Authorization Policy:**

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US \$30.00 per copy is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [1-58829-327-0/06 \$30.00].

Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1

eISBN 1-59745-148-7

#### **Library of Congress Cataloging-in-Publication Data**

Deoxynucleoside analogs in cancer therapy / edited by Godefridus J. Peters.

p. ; cm. -- (Cancer drug discovery and development)

Includes bibliographical references and index.

ISBN 1-58829-327-0 (alk. paper)

1. Deoxyribonucleotides--Therapeutic use. 2. Antineoplastic agents.

3. Cancer--Chemotherapy. I. Peters, Godefridus Johannes, 1952- . II. Series.

[DNLM: 1. Deoxyribonucleotides--therapeutic use. 2. Antineoplastic Agents--therapeutic use. 3. Neoplasms--drug therapy. QV 185 D418 2006]

RC271.C5D45 2006

616.99'4061--dc22

2005036304

# PREFACE

---

Successful cancer chemotherapy relies heavily on the application of various deoxynucleoside analogs. Since the very beginning of modern cancer chemotherapy, a number of antimetabolites have been introduced into the clinic and subsequently applied widely for the treatment of many malignancies, both solid tumors and hematological disorders. In the latter diseases, cytarabine has been the mainstay of treatment of acute myeloid leukemia. Although many novel compounds were synthesized in the 1980s and 1990s, no real improvement was made. However, novel technology is now capable of elucidating the molecular basis of several inborn errors as well as some specific malignancies. This has enabled the synthesis of several deoxynucleoside analogs that could be applied for specific malignancies, such as pentostatin and subsequently chlorodeoxyadenosine (cladribine) for the treatment of hairy cell leukemia. Already in the early stage of deoxynucleoside analog development, it was recognized that several of these compounds were very effective in the treatment of various viral infections, such as for the treatment of herpes infections. This formed the basis initially for the design of azidothymidine and subsequently many other analogs, which are currently successfully used for the treatment of HIV infections. As a spin-off of these research lines, some compounds not eligible for development as antiviral agents appeared to be very potent anticancer agents. The classical example is gemcitabine, now one of the most widely applied deoxynucleoside analogs, used for the (combination) treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer, and ovarian cancer. The knowledge gained with the development of all of these compounds formed the basis for the design of a number of novel analogs currently being used for the treatment of various malignancies or currently in an advanced stage of development. Interestingly, several of the nucleoside analogs are also targeted directly against cell cycle regulatory proteins as well as other protein kinases.

In this volume of the Cancer Drug Discovery and Development series, the current status of development and application of deoxynucleoside analogs has been summarized. A number of scientists well known in their specific area contributed with authoritative up-to-date reviews of their field. Their contributions were not limited to writing, but also included sound advice on structure and topics that was extremely valuable. *Deoxynucleoside Analogs in Cancer Therapy* is organized into several parts: the first part (Chapters 1–5) deals with general aspects of drug uptake and metabolism, the second deals with a number of specific drugs (Chapters 6–12),

while the last part covers pharmacokinetics, prodrugs, and specific applications such as radiosensitization and the use of deoxynucleoside analogs as tracers.

In order to be taken up by the cell, deoxynucleoside analogs require specific transporters, whereas other transporters can mediate efflux of (monophosphorylated) nucleosides. Novel technology enabled a rapid expansion of this field in the last decade (Chapters 1–5). Subsequent phosphorylation of nucleoside analogs is essential for their action and is mediated by a number of specific and less-specific deoxynucleoside kinases; their characteristics and regulation are summarized in Chapters 2 and 3. The role of nucleotidases in resistance to nucleoside analogs is described in Chapter 4. Specific viral deoxynucleoside kinases were recognized to be very suitable for local activation of otherwise inactive deoxynucleoside analogs. The HSV-specific thymidine kinase was therefore extensively used in early gene therapy studies. More active deoxynucleoside kinases with broad substrate specificity seem very suitable for future gene therapy applications, as described in Chapters 3 and 16.

A chapter on cytarabine—the first real deoxynucleoside analog widely used in the clinic—is essential to a complete book (Chapter 6). Various novel deoxynucleoside analogs have been developed in the last decade; several aspects of their mechanism of action and applications have been described throughout the above-mentioned chapters, while several of these analogs are described extensively in specific chapters on gemcitabine (Chapters 11 and 12), troxacitabine (Chapter 9), clofarabine, which was approved recently for acute leukemia (Chapter 7), and ara-G (Chapter 10). Two additional chapters deal with prodrug design (Chapter 15) or the novel class of L-nucleosides (Chapter 8).

Modern drug development tends to focus on specific targets, thereby neglecting that, in order to be effective, a drug needs to be taken up by the body and transported to the malignant tissues. A proper understanding of pharmacokinetics and pharmacodynamics of deoxynucleoside analogs is indispensable to their administration (Chapter 14). Also, pharmacogenomics, specific genetic properties of a tumor or a subject, determines whether a tumor will be sensitive to a drug and whether a patient will tolerate a drug. Proper knowledge of a patient's pharmacogenomics profile enables individualized treatment, as described in chapters on specific drugs.

Deoxynucleoside analogs can be considered ideal compounds to be combined with other drugs, either with classical cytotoxic agents or with novel so-called targeted agents such as cell cycle-directed compounds, various protein kinase inhibitors, and angiogenesis inhibitors. These applications are also described in specific chapters, while a specific chapter is dedicated to the excellent radiosensitizing properties of deoxynucleoside analogs (Chapter 13). The last chapter focuses on a novel application of a deoxynucleoside analog, the use of 3'-deoxy-3'-fluorothymidine as

an active tracer in PET with the potential to replace fluorodeoxyglucose in specific applications (Chapter 17).

Throughout *Deoxynucleoside Analogs in Cancer Therapy*, the focus is on novel aspects of deoxynucleoside analogs in the clinical context, as well as on unexpected targets of these compounds, such as their specific activity against cell cycle-dependent kinases or oncogenes. Modern targeted cancer chemotherapy aims to be more specific than in the past, but it has now been recognized that inhibition of just one target often enables the cell to find another pathway, bypassing this inhibition. Current knowledge of deoxynucleoside analogs has already led to successful combinations with novel targeted agents that prevent inhibition of one target from being bypassed by simultaneous activation of another. Future research in this field should use this knowledge to design rational combinations aimed at inhibiting various cellular signaling pathways, enhancing apoptotic pathways, or combining inhibition of various targets. *Deoxynucleoside Analogs in Cancer Therapy* has been designed specifically to facilitate such an interaction between various fields.

*Godefridus J. Peters, PhD*

# CONTENTS

---

Preface .....	v
Contributors .....	xi
1 Nucleoside Transport Into Cells: <i>Role of Nucleoside Transporters SLC28 and SLC29 in Cancer Chemotherapy</i> <i>Marçal Pastor-Anglada and F. Javier Casado</i> .....	1
2 The Role of Deoxycytidine Kinase in DNA Synthesis and Nucleoside Analog Activation <i>Maria Staub and Staffan Eriksson</i> .....	29
3 Deoxynucleoside Kinases and Their Potential Role in Deoxynucleoside Cytotoxicity <i>Birgitte Munch-Petersen and Jure Piškur</i> .....	53
4 Nucleotidases and Nucleoside Analog Cytotoxicity <i>Sally Anne Hunsucker, Beverly S. Mitchell, and Jozef Spsychala</i> .....	81
5 Pumping Out Drugs: <i>The Potential Impact of ABC Transporters on Resistance to Base, Nucleoside, and Nucleotide Analogs</i> <i>Piet Borst and Peter Wielinga</i> .....	109
6 Cytosine Arabinoside: <i>Metabolism, Mechanisms of Resistance, and Clinical Pharmacology</i> <i>Isabelle Hubeek, Gert-Jan L. Kaspers, Gert J. Ossenkoppele, and Godefridus J. Peters</i> .....	119
7 Clofarabine: <i>Mechanisms of Action, Pharmacology, and Clinical Investigations</i> <i>Varsha Gandhi and William Plunkett</i> .....	153
8 L-Nucleosides as Chemotherapeutic Agents <i>Giuseppe Gumina, Youhoon Chong, and Chung K. Chu</i> .....	173
9 Troxacitabine (Troxaty <sup>TM</sup> ): <i>A Deoxycytidine Nucleoside Analog With Potent Antitumor Activity</i> <i>Henriette Gourdeau and Jacques Jolivet</i> .....	199
10 9-β-D-Arabinofuranosylguanine <i>Sophie Curbo and Anna Karlsson</i> .....	215



---

11	Gemcitabine: <i>Mechanism of Action and Resistance</i> <i>Andries M. Bergman and Godefridus J. Peters</i> .....	225
12	Clinical Activity of Gemcitabine as a Single Agent and in Combination <i>Judith R. Kroep, Godefridus J. Peters, and Robert A. Nagourney</i> .....	253
13	Nucleoside Radiosensitizers <i>Donna S. Shewach and Theodore S. Lawrence</i> .....	289
14	NONMEM Population Models of Cytosine Arabinoside and Fludarabine Phosphate in Pediatric Patients With Leukemia <i>Vassilios I. Avramis</i> .....	331
15	The <i>cycloSal</i> -Nucleotide Delivery System: <i>Development</i> <i>of Chemical Trojan Horses as Antiviral Agents</i> <i>Chris Meier, Jan Balzarini, and Astrid Meerbach</i> .....	353
16	Purine and Pyrimidine-Based Analogs and Suicide Gene Therapy <i>Zoran Gojkovic and Anna Karlsson</i> .....	403
17	3'-Deoxy-3'-Fluorothymidine as a Tracer of Proliferation in Positron Emission Tomography <i>Wieteke G. E. Direcks, Adriaan A. Lammertsma,</i> <i>and Carla F. M. Molthoff</i> .....	441
	Index .....	463

# CONTRIBUTORS

---

- VASSILIOS I. AVRAMIS, PhD • *Keck School of Medicine, University of Southern California; Department of Pediatrics, Division of Hematology/Oncology, Childrens Hospital Los Angeles, Los Angeles, CA*
- JAN BALZARINI, PhD • *Professor, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium*
- ANDRIES M. BERGMAN, MD, PhD • *Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands*
- PIET BORST, MD, PhD • *Professor, Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands*
- F. JAVIER CASADO, MSc, PhD • *Associate Professor of Biochemistry and Molecular Biology, Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain*
- YOUHOON CHONG, PhD • *Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA*
- CHUNG K. CHU, PhD • *Distinguished Research Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA*
- SOPHIE CURBO, PhD • *Department of Laboratory Medicine, Division of Metabolic Disorders, Karolinska Institutet, Stockholm, Sweden*
- WIETEKE G. E. DIRECKS, MSc • *Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands*
- STAFFAN ERIKSSON, MD, PhD • *Professor of Medical and Physiological Chemistry, Department of Molecular Biosciences, The Swedish University of Agricultural Sciences, The Biomedical Center, Uppsala, Sweden*
- VARSHA GANDHI, PhD • *Department of Experimental Therapeutics, The University of Texas, M. D. Anderson Cancer Center, Houston, TX*
- ZORAN GOJKOVIC, PhD • *ZGene A/S, Hørsholm, Denmark*
- HENRIETTE GOURDEAU, PhD • *Associate Director, Pharmacology/Toxicology, Ecopia BioSciences Inc., Ville Saint-Laurent, Québec, Canada*
- GIUSEPPE GUMINA, PhD • *Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC*

- ISABELLE HUBEEK, PhD • *Department of Pediatric Hematology/Oncology, VU University Medical Center, Amsterdam, The Netherlands*
- SALLY ANNE HUNSUCKER, PhD • *Lineberger Comprehensive Cancer Center, Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC*
- JACQUES JOLIVET, MD • *Vice-President of Clinical Development, Aegera Therapeutics Inc., Montreal, Québec, Canada*
- ANNA KARLSSON, MD, PhD • *Department of Laboratory Medicine, Division of Metabolic Disorders, Karolinska Institutet, Stockholm, Sweden*
- GERT-JAN L. KASPERS, MD, PhD • *Department of Pediatric Hematology, VU University Medical Center, Amsterdam, The Netherlands*
- JUDITH R. KROEP, MD, PhD • *Department Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands*
- ADRIAAN A. LAMMERTSMA, PhD • *Professor, Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands*
- THEODORE S. LAWRENCE, MD, PhD • *Professor, Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI*
- ASTRID MEERBACH, PhD • *Institute for Virology and Antiviral Therapy, Friedrich-Schiller-University Jena, Jena, Germany*
- CHRIS MEIER, PhD • *Professor, Institute of Organic Chemistry, University of Hamburg, Hamburg, Germany*
- BEVERLY S. MITCHELL, MD, PhD • *George E. Becker Professor of Medicine, Comprehensive Cancer Center, Stanford University, Stanford, CA*
- CARLA F. M. MOLTHOFF, PhD • *Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands*
- BIRGITTE MUNCH-PETERSEN, DSc • *Professor, Department of Life Sciences and Chemistry, Roskilde University, Roskilde, Denmark*
- ROBERT A. NAGOURNEY, MD • *Rational Therapeutics Inc., Malcolm C. Todd Cancer Institute, Long Beach, CA*
- GERT J. OSSENKOPPELE, MD, PhD • *Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands*
- MARÇAL PASTOR-ANGLADA, MSc, PhD • *Professor of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain*
- GODEFRIDUS J. PETERS, PhD • *Professor, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands*

JURE PIŠKUR, PhD • *Professor, Department of Cell and Organism Biology,  
Lund University, Lund, Sweden*

WILLIAM PLUNKETT, PhD • *Department of Experimental Therapeutics,  
The University of Texas, M. D. Anderson Cancer Center, Houston, TX*

DONNA S. SHEWACH, PhD • *Professor, Department of Pharmacology,  
University of Michigan Medical School, Ann Arbor, MI*

JOZEF SPYCHALA, PhD • *President, VisiScience Corporation, Chapel Hill, NC;  
Department of Pharmacology, Lineberger Comprehensive Cancer Center,  
University of North Carolina at Chapel Hill, Chapel Hill, NC*

MARIA STAUB, MD, PhD, ScD • *Professor of Medical Biochemistry, Department  
of Medical Chemistry, Molecular Biology and Pathobiochemistry, Faculty  
of Medicine, Semmelweis University, Budapest, Hungary*

PETER WIELINGA, PhD • *National Institute for Public Health and Environment  
(RIVM), Bilthoven, The Netherlands*